Adam’s journey demonstrates an inspiring blend of vision, perseverance, and adaptability required to navigate the complex landscape of building and scaling a company–particularly one that transitioned from a private entity to a publicly traded powerhouse.
The post Adam Mendelsohn On Raising $100 Million To Develop A Portfolio Of Miniature, Long-Term Implants To Deliver Drugs More Efficiently And Consistently appeared first on Alejandro Cremades.
No transcript available.
POWERED BY BLUBRRY
